TY  - GEN
AU  - Lopez-Corral, Lucia
AU  - Caballero-Velazquez, Teresa
AU  - Lopez-Godino, Oriana
AU  - Rosinol, Laura
AU  - Perez-Vicente, Sabina
AU  - Fernandez-Aviles, Francesc
AU  - Krsnik, Isabel
AU  - Morillo, Daniel
AU  - Heras, Inmaculada
AU  - Morgades, Mireia
AU  - Rifon, Jose J
AU  - Sampol Mayol, Antonia
AU  - Iniesta, Francisca
AU  - Ocio, Enrique-Maria
AU  - Martin, Jesus
AU  - Rovira, Montserrat
AU  - Cabero, Martin
AU  - Castilla-Llorente, Cristina
AU  - Ribera, Josep-Maria
AU  - Torres-Juan, Marta
AU  - Maria Moraleda, Jose
AU  - Martinez, Carmen
AU  - Vazquez, Alejandro
AU  - Gutierrez, Gonzalo
AU  - Caballero, Dolores
AU  - San Miguel, Jesus F
AU  - Mateos, Maria-Victoria
AU  - Perez-Simon, Jose Antonio
PY  - 2019
DO  - 10.1016/j.bbmt.2019.04.026
SN  - 1083-8791
UR  - https://hdl.handle.net/20.500.12105/22690
AB  - Multiple myeloma (MM) remains as an incurable disease and, although allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative approach, most patients ultimately relapse, and their treatment remains challenging. Because...
LA  - eng
PB  - Elsevier
KW  - Multiple myeloma
KW  - Allogeneic hematopoietic stem cell transplantation
KW  - Allo-HSCT
KW  - Proteasome inhibitor
KW  - Immunomodulatory drug
KW  - Disease-Free Survival
KW  - Aged
KW  - Allografts
KW  - Hematopoietic Stem Cell Transplantation
KW  - Spain
KW  - Adult
KW  - Follow-Up Studies
KW  - Humans
KW  - Middle Aged
KW  - Immunologic Factors
KW  - Recurrence
KW  - Graft vs Host Disease
KW  - Male
KW  - Multiple Myeloma
KW  - Proteasome Inhibitors
KW  - Female
KW  - Survival Rate
KW  - Incidence
KW  - Retrospective Studies
TI  - Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma
TY  - research article
ER  -